

Review paper

Mitochondrial RNAs in Oncology: Review of Interventions and Innovative Diagnostic Approaches in the Biogenesis of Human Cancers

Pezhman Shafiei Asheghabadi^{1,2,3*}, Asma Delavari Dosar^{2,4}, Mehrdad Hashemi^{2,5}

¹ Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

² Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

³ Biology Association, Young Researchers and Elite Club, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

⁴ Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran

⁵ Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

Received: 23 April 2024

Revised: 28 April 2024

Accepted: 1 May 2024

Abstract

Background and Aim: Cancer is the greatest public health challenge of the 21st century, with most patients diagnosed at advanced stages. Recent research highlights non-coding nuclear-encoded mitochondrial RNAs (mtRNAs) as potential biomarkers for cancer diagnosis. This study explores the mtRNA family and their diagnostic applications in oncology, including chromatin-associated mitochondrial RNAs (mt-caRNA), long non-coding mitochondrial RNAs (ncmtRNA), mitochondrial messenger RNA (mito-mRNA), mitochondrial transfer RNA (mito-tRNA), mitochondrial microRNAs (mito-miRNA), and circular mitochondrial RNAs (circ-mtRNA).

Methods: A comprehensive search in PubMed and Google Scholar (2022-2024) yielded 21 articles related to "Diagnosis", "Oncology", "Cancer", and "Mitochondrial RNA".

Results: Changes in mtRNA levels impact cancer progression by affecting mitochondrial protein synthesis and apoptosis. mt-caRNAs facilitate mitochondrial-nuclear communication, and ncmtRNAs like ncmtRNA-LDL805 influence mitochondrial bioenergetics in lung diseases. Specific mtRNA changes could be therapeutic targets against metastasis. QUCO-1 binds mtRNA, causing mitochondrial dysfunction, apoptosis, cell cycle arrest, and reduced proliferation in colorectal cancer cells. Reduced circ-mtRNA expression is linked to tumor size and recurrence. Targeting AsncmtRNAs with ASOs suppresses breast cancer cell proliferation and induces apoptosis.

Conclusion: Mitochondrial RNAs (mtRNAs) play a role in cell biogenesis and mitochondrial regulation, potentially providing new diagnostic and predictive cancer methods.

Keywords: *mtRNAs, Oncology, Cancer, Diagnosis*

***Corresponding author:** Pezhman Shafiei Asheghabadi, Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

E-mail address: p.shafiei@student.iautmu.ac.ir

Introduction

Cancer is the greatest human public health challenge of the 21st century [1]. Most patients are diagnosed in advanced stages, underscoring the significant importance of diagnostic approaches [2], [3], [4]. Recent research has introduced non-coding nuclear-encoded mitochondrial RNAs (mtRNAs) as potential biomarkers for cancer diagnosis [2], [5]. In this study, we describe the mtRNA family and their diagnostic approaches in oncology, including chromatin-associated mitochondrial RNAs (mt-caRNA) [6], long non-coding mitochondrial RNAs (ncmtRNA) [7], [8], mitochondrial messenger RNA (mito-mRNA) [9], mitochondrial transfer RNA (mito-tRNA) [5], [10], [11], mitochondrial microRNAs (mito-miRNA) [12], and circular mitochondrial RNAs (circ-mtRNA) [11], [13].

1. Chromatin-Associated Mitochondrial RNAs

Recent research indicates that these molecules originate from the nuclear genome and bind to it, forming part of the caRNA family [6]. These molecules preferentially attach to promoter regions, and their binding levels change in response to environmental stresses, such as diabetes [6]. Suppressing certain non-coding types of these RNAs in human endothelial cells reduces the expression of RNA molecules that regulate cellular adhesion [6]. Additionally, many mt-caRNAs are translocated to the nucleus under cellular stress and disease conditions, identifying these molecules as messengers responsible for mitochondrial-nuclear communication and linking mitochondrial genome transcription products with nuclear transcription regulation [6].

2. Long Non-Coding Mitochondrial RNAs

The levels of mitochondrial non-coding RNAs (ncRNAs) increase in type 2 alveolar epithelial cells of both mice and humans when exposed to cigarette smoke. These molecules potentially play a significant role in mitochondrial biogenesis in human lung cells, possibly linking them to lung diseases [7]. They mediate mitochondrial bioenergetics in type 2 alveolar epithelial cells in response to cigarette smoke exposure; however, this response might diminish in smoking-related abnormalities like chronic obstructive pulmonary disease (COPD) or non-small cell lung cancer (NSCLC) due to their reduction [7]. The mitochondrial long non-coding RNA (lncRNAs) family comprises sense (SncmtRNA) and antisense (ASncmtRNA) members [8]. Suppression of ASncmtRNAs using antisense oligonucleotides (ASOs) halts proliferation and induces apoptosis in tumor cells, but not in normal cells [8]. A 2023 study using RNA sequencing (RNAseq) on MDA-MB-231 breast cancer cells revealed no significant differences in mRNA levels, although proteins responsible for genomic integrity were downregulated in tumor cells and upregulated in normal cells. This inverse effect of ASncmtRNA likely contributes to tumor cell suppression and protection of normal cells [8].

3. Mitochondrial Messenger RNA

Given the fundamental relationship between DNA and proteins, with mRNA serving as the primary intermediary, targeting mitochondrial mRNA translation could yield beneficial anti-cancer effects [14]. Aggressive cancers often exhibit increased metabolic flexibility, with this metabolic switch facilitating tumor growth being pharmacologically targetable through inhibition of mitochondrial mRNA translation [14]. These specific mtRNA alterations could serve as therapeutic targets against metastatic cancers [14].

4. Mitochondrial Transfer RNA

The human mitochondrion contains 20 amino acids, with 18 having unique tRNA matches, except for tRNA^{Leu} and tRNA^{Ser}, which have two iso receptors [15]. Mutations or disruptions in any tRNA can impair mitochondrial protein translation [15]. Cancer cells primarily rely on oxidative phosphorylation (OXPHOS) for energy, and defective proteins can positively or negatively impact

cancer development [15]. Defective mitochondrial tRNA modifications are closely associated with mitochondrial diseases [15]. Evidence suggests a strong link between mitochondrial tRNA changes and tumor progression [15]. Recent studies show that tRNA methyltransferase 5 (TRMT5) catalyzes the modification of mitochondrial tRNA m1G37, promoting hepatocellular carcinoma (HCC) progression [15]. TRMT5 expression is upregulated in HCC and linked to poor prognosis [15]. Silencing TRMT5 reduces HCC proliferation and metastasis both “in vivo” and “in vitro”, increasing tumor cell sensitivity to chemotherapy, positioning TRMT5 as a potential oncogene and therapeutic target [15]. Additionally, small tRNA-derived RNAs (tsRNAs) play critical roles in tumorigenesis and are stable in circulation, making serum tsRNA signatures potential new biomarkers for HCC [16].

5. Mitochondrial MicroRNAs

Mitochondria-associated miRNAs have been identified as potential biomarkers involved in mitochondrial abnormalities [12]. These miRNAs regulate various aspects of mitochondrial homeostasis, including respiratory chain expression and assembly, mitochondrial biogenesis, antioxidant capacity, and apoptosis [12]. miRNAs translocated from the nucleus to mitochondria modulate mitochondrial genome translation [17]. mitomiR-2392, for instance, influences chemoresistance in tongue squamous cell carcinoma (TSCC) cells by reprogramming metabolism, decreasing OXPHOS, and increasing glycolysis [17]. Analyses of TSCC tumors show significant associations between miR-2392, mitochondrial gene expression, chemoresistance, and overall survival [17]. Mito-miRNAs play roles in mitochondrial DNA (mtDNA) transcription, cellular metabolism, and chemoresistance [17].

6. Mitochondrial Circular RNAs

Research on circRNAs has largely focused on those encoded by the nuclear genome, with limited information on mitochondria-derived circRNAs [13]. circRNAs show promise as biomarkers for various cancers [11]. The human mitochondrion encodes 13 proteins, 2 rRNAs, and 22 tRNAs [18]. Nuclear genome diversity alone cannot fully explain mitochondrial diseases [18]. Recent evidence suggests circRNAs are found in mitochondria, derived from both mitochondrial and nuclear genomes, and associated with various diseases, especially cancers [18]. These circRNAs play regulatory roles in cellular and molecular physiology and pathology [18]. mito-circRNAs are implicated in regulating mitochondrial-derived ROS production, although their exact functions remain unknown [19]. circPUM1, derived from back-splicing of the nuclear genome's PUM1 mRNA, is translocated to mitochondria and positively correlated with HIF1 α accumulation under hypoxic conditions induced by CoCl₂ in esophageal squamous cell carcinoma (ESCC) cell lines [20]. Suppression of circPUM1 reduces intracellular oxygen concentration, OXPHOS, mitochondrial membrane potential, increases ROS production, and mitochondrial shrinkage, leading to mitochondrial complex III dysfunction and caspase 3 dissociation [20]. Notably, circPUM1 disruption induces pyroptosis, initiating ESCC cell death [20]. Therefore, circPUM1 is crucial for maintaining mitochondrial complex III stability to enhance OXPHOS for ATP production in ESCC cells [20].

Methods

It was conducted a comprehensive search in PubMed and Google Scholar databases from 2022 to 2024, identified 21 articles relevant to the main topic of this paper. The search terms used included "Diagnosis", "Oncology", "Cancer", and "Mitochondrial RNA".

Results and Discussion

Changes in mtRNA levels are associated with cancer growth and progression [8], [10], [11], [15], [21], [22], [23], playing a significant role in mitochondrial protein synthesis, with their interventions in the mitochondrial outer membrane being an effective pathway for inducing cellular apoptosis [24], [25]. mt-caRNAs are involved in mitochondrial-nuclear communication, linking mitochondrial transcription products with the regulation of nuclear genome transcription [6]. Some ncmtRNAs, such as ncmtRNA-LDL805, mediate mitochondrial bioenergetics in type 2 alveolar epithelial cells of mice and humans exposed to cigarette smoke, potentially associated with lung-related diseases like lung cancer [7]. Recent research also suggests that specific mtRNA alterations could serve as therapeutic targets against metastasis [14]. Given the well-established potential role of mitochondria in oncology [2], [3], the regulation of mito-tRNA function is crucial due to its close association with mitochondrial diseases, particularly in cancer biogenesis [10], [15].

QUCO-1 (a fluorescent quinolinium derivative) illuminates with mtRNA under “In Vitro” conditions, inducing severe mitochondrial dysfunction and inhibition of OXPHOS in colorectal cancer (RKO) cells, leading to apoptosis, G2/M cell cycle arrest, and effective inhibition of cell proliferation upon QUCO-1 treatment [26]. Additionally, mito-miRNAs and circ-mtRNAs playing a significant role in oncology [11], [12]. For instance, reduced expression of circ-mtRNAs correlates significantly with tumor size and predicts cancer recurrence, while optimizing their translation may prevent gastric cancer progression by regulating cell proliferation, apoptosis, and tumor invasion [27]. Furthermore, it has been demonstrated that suppression of AsncmtRNAs using antisense oligonucleotides (ASOs) leads to the inhibition of proliferation and apoptosis in breast cancer tumor cells [8].

Conclusion

We have identified mtRNAs as molecules involved in the biogenesis of both normal and cancer human cells, particularly in regulating mitochondrial function, offering promising prospects for new cancer diagnostic and predictive approaches.

Acknowledgment

We thank all contributors for their invaluable support and assistance.

Conflict of Interests

The authors declare that there are no competing interests.

Reference

- [1]. Kuo JY, Liao CL, Ma YS, Kuo CL, Chen JC, Huang YP, Huang WW, Peng SF, Chung JG. Combination treatment of sorafenib and bufalin induces apoptosis in NCI-H292 human lung cancer cells in vitro. *in vivo*. 2022;36(2):582-95.
- [2]. Zhou Q, Xiong J, Gao Y, Yi R, Xu Y, Chen Q, Wang L, Chen Y. Mitochondria-related lncRNAs: predicting prognosis, tumor microenvironment and treatment response in lung adenocarcinoma. *Functional & Integrative Genomics*. 2023;23(4):323.
- [3]. Yang M, Wang X, Ye Z, Liu T, Meng Y, Duan Y, Yuan X, Yue X, Deng W, Liu RY. Mitochondrial creatine kinase 1 regulates the cell cycle in non-small cell lung cancer via activation of cyclin-dependent kinase 4. *Respiratory Research*. 2023;24(1):111.

- [4]. Hoang DH, Song M, Kovale LM, Tran QH, Choe W, Kang I, Kim SS, Ha J. Betanaphthoflavone and doxorubicin synergistically enhance apoptosis in human lung cancer cells by inducing doxorubicin accumulation, mitochondrial ROS generation, and JNK pathway signaling. *Biochemical and Biophysical Research Communications*. 2022;635:37-45.
- [5]. Rosolen D, Nunes-Souza E, Marchi R, Tofolo MV, Antunes VC, Berti FC, Fonseca AS, Cavalli LR. MiRNAs action and impact on mitochondria function, metabolic reprogramming and chemoresistance of cancer cells: a systematic review. *Biomedicines*. 2023;11(3):693.
- [6]. Sriram K, Qi Z, Yuan D, Malhi NK, Liu X, Calandrelli R, Luo Y, Tapia A, Jin S, Shi J, Salas M, Dang R, Armstrong B, Priceman SJ, Wang PH, Liao J, Natarajan R, Zhong S, Chen ZB. Regulation of nuclear transcription by mitochondrial RNA in endothelial cells. *Elife*. 2024;13:e86204.
- [7]. Mathuram TL, Su Y, Bard J, Perry NA, Chen CW, Warren MT, Linden PA, Perry Y, Hatzoglou M, Wu Y, Blumental-Perry A. Mitochondrial ncRNA LDL-805 declines in alveolar epithelial type 2 cells of chronic obstructive pulmonary disease patients. *bioRxiv*. 2024:2024-01.
- [8]. Bendek MF, Fitzpatrick C, Jeldes E, Boland A, Deleuze JF, Farfán N, Villegas J, Nardocci G, Montecino M, Burzio LO, Burzio VA. Inverse Modulation of Aurora Kinase A and Topoisomerase II α in Normal and Tumor Breast Cells upon Knockdown of Mitochondrial ASncmtRNA. *Non-coding RNA*. 2023;9(5):59.
- [9]. Fernando CD, Jayasekara WS, Inampudi C, Kohonen-Corish MR, Cooper WA, Beilharz TH, Josephs TM, Garama DJ, Gough DJ. A STAT3 protein complex required for mitochondrial mRNA stability and cancer. *Cell Reports*. 2023;42(9).
- [10]. Zhao Q, Zhang L, He Q, Chang H, Wang Z, Cao H, Zhou Y, Pan R, Chen Y. Targeting TRMT5 suppresses hepatocellular carcinoma progression via inhibiting the HIF-1 α pathways. *Journal of Zhejiang University-SCIENCE B*. 2023;24(1):50-63.
- [11]. Cheng X, Shen C, Liao Z. High Expression of Circular RNA-Mitochondrial tRNA Translation Optimization 1 Assists the Diagnosis of High-Risk Human Papillomavirus Infection in Cervical Cancer. *J Low Genit Tract Dis*. 2022;26(3):212-8.
- [12]. Gambardella J, Fiordelisi A, Sorriento D, Cerasuolo F, Buonaiuto A, Avvisato R, Pisani A, Varzideh F, Riccio E, Santulli G, Iaccarino G. Mitochondrial microRNAs are dysregulated in patients with Fabry Disease. *Journal of Pharmacology and Experimental Therapeutics*. 2023;384(1):72-8.
- [13]. Luan J, Jiao C, Ma C, Zhang Y, Hao X, Zhou G, Fu J, Qiu X, Li H, Yang W, Illei GG, Kopp JB, Pi J, Zhou H. circMTND5 participates in renal mitochondrial injury and fibrosis by sponging MIR6812 in lupus nephritis. *Oxidative Medicine and Cellular Longevity*. 2022;2022(1):2769487.
- [14]. Delaunay S, Pascual G, Feng B, Klann K, Behm M, Hotz-Wagenblatt A, Richter K, Zaoui K, Herpel E, Münch C, Dietmann S, Hess J, Benitah SA, Frye M. Mitochondrial RNA modifications shape metabolic plasticity in metastasis. *Nature*. 2022;607(7919):593-603.
- [15]. Bian P, Chai J, Xu B. Research Advances on Deafness Genes Associated with Mitochondrial tRNA-37 Modifications. *J Int Adv Otol*. 2023;19(5):414-9.
- [16]. Zhan S, Yang P, Zhou S, Xu Y, Xu R, Liang G, Zhang C, Chen X, Yang L, Jin F, Wang Y. Serum mitochondrial tsRNA serves as a novel biomarker for hepatocarcinoma diagnosis. *Frontiers of Medicine*. 2022;16(2):216-26.
- [17]. Fan S, Tian T, Chen W, Lv X, Lei X, Zhang H, Sun S, Cai L, Pan G, He L, Ou Z, Lin X, Wang X, Perez MF, Tu Z, Ferrone S, Tannous BA, Li J. Mitochondrial miRNA determines chemoresistance by reprogramming metabolism and regulating mitochondrial transcription. *Cancer research*. 2019;79(6):1069-84.

- [18]. Liu D, Zhou X, He Y, Zhao J. The Roles of CircRNAs in Mitochondria. *J Cancer*. 2024;15(9):2759-69.
- [19]. Zheng H, Huang S, Wei G, Sun Y, Li C, Si X, Chen Y, Tang Z, Li X, Chen Y, Liao W, Liao Y, Bin J. CircRNA Samd4 induces cardiac repair after myocardial infarction by blocking mitochondria-derived ROS output. *Molecular Therapy*. 2022;30(11):3477-98.
- [20]. Gong W, Xu J, Wang Y, Min Q, Chen X, Zhang W, Chen J, Zhan Q. Nuclear genome-derived circular RNA circPUM1 localizes in mitochondria and regulates oxidative phosphorylation in esophageal squamous cell carcinoma. *Signal Transduction and Targeted Therapy*. 2022;7(1):40.
- [21]. Chaddha M, Rai H, Gupta R, Thakral D. Integrated analysis of circulating cell free nucleic acids for cancer genotyping and immune phenotyping of tumor microenvironment. *Front Genet*. 2023;14:1138625.
- [22]. Zhou J, Qiu C, Tang X, Wan R, Wu Z, Zou D, Wang W, Luo Y, Liu T. Investigation of the clinicopathological and prognostic role of circMTO1 in multiple cancers. *Expert Review of Molecular Diagnostics*. 2023;23(2):159-70.
- [23]. Chang C, Zheng A, Wang P, Teng X. Circular RNA mitochondrial translation optimization 1 correlates with less lymph node metastasis, longer disease-free survival, and higher chemotherapy sensitivity in gastric cancer. *J Clin Lab Anal*. 2022;36(6):e23918.
- [24]. Feng Y, Fang J, Zhao Y, Ye S, Wang A, Zhang Y, Zhu J, Li J, Lv Z, Zhao Z, Shi H. NIR Light-Mediated Mitochondrial RNA Modification for Cancer RNA Interference Therapeutics. *Angewandte Chemie International Edition*. 2023;62(19):e202218969.
- [25]. Killarney ST, Washart R, Soderquist RS, Hoj JP, Lebhar J, Lin KH, Wood KC. Executioner caspases restrict mitochondrial RNA-driven Type I IFN induction during chemotherapy-induced apoptosis. *Nature Communications*. 2023;14(1):1399.
- [26]. Wang BZ, Zhou YC, Lin YW, Chen XC, Yu ZY, Xu YH, Tan JH, Huang ZS, Chen SB. Fluorescent Quinolinium Derivative as Novel Mitochondria Probe and Function Modulator by Targeting Mitochondrial RNA. *Molecules*. 2023;28(6):2690.
- [27]. Mance LG, Mawla I, Shell SM, Cahoon AB. Mitochondrial mRNA fragments are circularized in a human HEK cell line. *Mitochondrion [Internet]*. 2020;51:1-6.